Lo, Y. D. et al. Rapid clearance of fetal DNA from maternal plasma. Am. J. Hum. Genet. 64, 218–224 (1999).
Google Scholar
Diehl, F. et al. Circulating mutant DNA to assess tumour dynamics. Nat. Med. 14, 985–990 (2008).
Google Scholar
Jahr, S. et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61, 1659–1665 (2001).
Google Scholar
Wan, J. C. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223–238 (2017).
Google Scholar
Diaz, L. A. Jr & Bardelli, A. Liquid biopsies: genotyping circulating tumour DNA. J. Clin. Oncol. 32, 579–586 (2014).
Google Scholar
Thierry, A. R. et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumour DNA. Nat. Med. 20, 430–435 (2014).
Google Scholar
Alix-Panabieres, C. & Pantel, K. Clinical applications of circulating tumour cells and circulating tumour DNA as liquid biopsy. Cancer Discov. 6, 479–491 (2016).
Google Scholar
Mok, T. et al. Detection and dynamic changes of EGFR mutations from circulating tumour DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin. Cancer Res. 21, 3196–3203 (2015).
Google Scholar
Hao, T. B. et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br. J. Cancer 111, 1482–1489 (2014).
Google Scholar
Azad, A. A. et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer Res. 21, 2315–2324 (2015).
Google Scholar
Lebofsky, R. et al. Circulating tumour DNA as a non-invasive substitute to metastasis biopsy for tumour genotyping and personalized medicine in a prospective trial across all tumour types. Mol. Oncol. 9, 783–790 (2015).
Google Scholar
Schwarzenbach, H., Hoon, D. S. B. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426–437 (2011).
Google Scholar
Goyal, L. et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 7, 252–263 (2016).
Google Scholar
Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and Food and Drug Administration Staff (US FDA, 2013); https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-vitro-diagnostic-productslabeled-research-use-only-or-investigational-use-only
Dietel, M. et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax 71, 177–184 (2015).
Google Scholar
Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550 (2016).
Google Scholar
Vansteenkiste, J. et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25, 7554 (2007).
Gettinger, S. N. et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33, 2004–2012 (2015).
Google Scholar
Burstein, H. J. et al. Clinical cancer advances 2017: annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol. 35, 1341–1367 (2017).
Google Scholar
Wender, R. et al. American Cancer Society lung cancer screening guidelines. CA Cancer J. Clin. 63, 107–117 (2013).
Google Scholar
Baldwin, D. R. et al. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax 66, 308–313 (2011).
Google Scholar
Field, J. K. et al. International association for the study of lung cancer computed tomography screening workshop 2011 report. J. Thorac. Oncol. 7, 10–19 (2012).
Google Scholar
Spigel, D. R. et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J. Clin. Oncol. 29, 7505 (2011).
Mok, T. S. et al. Osimertinib or platinum-pemetrexed in EGFR T790M positive lung cancer. N. Engl. J. Med. 376, 629–640 (2017).
Google Scholar
Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Lancet Oncol. 12, 735–742 (2011).
Google Scholar
Gatzemeier, U. et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 22, 7010 (2004).
Oxnard, G. R. et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J. Clin. Oncol. 34, 3375–3382 (2016).
Google Scholar
Clark, T. A. et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumour DNA. The. J. Mol. Diagnostics 20, 686–702 (2018).
Google Scholar
Lanman, R. B. et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumour DNA. PLoS ONE 10, e0140712 (2015).
Google Scholar
Paz-Ares, L. et al. plus chemotherapy for squamous non–small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018).
Google Scholar
Fabrizio, D. et al. A blood-based next-generation sequencing assay to determine tumour mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab. Cancer Res. 78, 5706–5706 (2018).
Hellmann, M. D. et al. (2018). Nivolumab plus ipilimumab in lung cancer with a high tumour mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).
Google Scholar
Gandara, D. R. et al. Blood-based tumour mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat. Med. 24, 1441–1448 (2018).
Google Scholar
Le, D. T. et al. PD-1 blockade in tumours with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
Google Scholar
Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumours to PD-1 blockade. Science 357, 409–413 (2017).
Google Scholar
Rolfo, C. et al. Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim. Biophys. Acta 1846, 539–546 (2014).
Google Scholar
Xiong, L. et al. Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients. Oncotarget 8, 63846–63856 (2017).
Google Scholar
Romano, G. et al. A preexisting rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer Discov. 8, 556–567 (2018).
Google Scholar
Goldberg, S. B. et al. Early assessment of lung cancer immunotherapy response via circulating tumour DNA. Clin. Cancer Res. 24, 1872–1880 (2018).
Google Scholar
Narayan, A. et al. Ultrasensitive measurement of hotspot mutations in tumour DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 72, 3492–3498 (2012).
Google Scholar
Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small-cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560–562 (2015).
Google Scholar
Kwong, L. N. et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat. Med. 18, 1503–1510 (2012).
Google Scholar
Wang, Z. et al. Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first-and third-generation EGFR TKIs and shifts allelic configuration at resistance. J. Thorac. Oncol. 12, 1723–1727 (2017).
Google Scholar
Corcoran, R. B. & Chabner, B. A. Application of cell-free DNA analysis to cancer treatment. N. Engl. J. Med. 379, 1754–1765 (2018).
Google Scholar
Garcia-Murillas, I. et al. Mutation tracking in circulating tumour DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7, 302ra133 (2015).
Google Scholar
Dawson, S. J. et al. Analysis of circulating tumour DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199–1209 (2013).
Google Scholar
Reinert, T. et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5, 1124–1131 (2019).
Google Scholar
Tie, J. et al. Circulating tumour DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).
Google Scholar
Abbosh, C., Birkbak, N. J. & Swanton, C. Early stage NSCLC—challenges to implementing ctDNA-based screening and MRD detection. Nat. Rev. Clin. Oncol. 15, 577–586 (2018).
Google Scholar
Oxnard, G. R. et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 20, 1698–1705 (2014).
Google Scholar
Phallen, J. et al. Direct detection of early-stage cancers using circulating tumour DNA. Sci. Transl. Med. 9, eaan2415 (2017).
Google Scholar
Imperiale, T. F. et al. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 370, 1287–1297 (2014).
Google Scholar
Chan, K. A. et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. 377, 513–522 (2017).
Google Scholar
Cohen, J. D. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926–930 (2018).
Google Scholar
Lecomte, T. et al. Detection of free circulating tumour associated DNA in plasma of colorectal cancer patients and its association with prognosis. N. Engl. J. Med. 370, 1287–1297 (2014).
Hu, Y. et al. False-positive plasma genotyping due to clonal hematopoiesis. Clin. Cancer Res. 24, 4437–4443 (2018).
Google Scholar
Heitzer, E., Haque, I. S., Roberts, C. E. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71–88 (2019).
Google Scholar
Sina, A. A. I. et al. Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker. Nat. Commun. 9, 4915 (2018).
Google Scholar
Lehmann-Werman, R. et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc. Natl Acad. Sci. USA 113, E1826–E1834 (2016).
Google Scholar
Deng, J. et al. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat. Biotechnol. 27, 353–360 (2009).
Google Scholar
Xu, R. H. et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat. Mater. 16, 1155–1161 (2017).
Google Scholar
Teschendorff, A. E. & Relton, C. L. Statistical and integrative system-level analysis of DNA methylation data. Nat. Rev. Genet. 19, 129–147 (2018).
Google Scholar
Guo, S. et al. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumour tissue-of-origin mapping from plasma DNA. Nat. Genet. 49, 635–642 (2017).
Google Scholar
Tug, S. et al. Exercise-induced increases in cell-free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. Exerc. Immunol. Rev. 21, 164–173 (2015).
Google Scholar
Moreira, V. G., Prieto, B., Rodr.ıguez, J. S. M. & Alvarez, F. V. Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. Ann. Clin. Biochem. 47, 253–258 (2010).
Google Scholar
Burnham, P. et al. Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract. Nat. Commun. 9, 2412 (2018).
Google Scholar
Siljan, W. W. et al. Circulating cell-free DNA is elevated in community acquired bacterial pneumonia and predicts short-term outcome. J. Infect. 73, 383–386 (2016).
Google Scholar
Lindahl, T. Instability and decay of the primary structure of DNA. Nature 362, 709–715 (1993).
Google Scholar
Richter, C., Park, J. W. & Ames, B. N. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl Acad. Sci. USA 85, 6465–6467 (1988).
Google Scholar
Cooke, M. S., Evans, M. D., Dizdaroglu, M. & Lunec, J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 17, 1195–1214 (2003).
Google Scholar
Norton, S. E., Lechner, J. M., Williams, T. & Fernando, M. R. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin. Biochem. 46, 1561–1565 (2013).
Google Scholar
Manning, J. E. in Emergency Medicine: A Comprehensive Study Guide (ed. Tintinalli, J. E.) 227 (McGraw-Hill, 2004).
Botezatu, I. et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin. Chem. 46, 1078–1084 (2000).
Google Scholar
Koide, K. et al. Fragmentation of cell-free fetal DNA in plasma and urine of pregnant women. Prenat. Diagnosis 25, 604–607 (2005).
Google Scholar
Tani, M. & Beck, S. Epigenome-wide association studies for cancer biomarker discovery in circulating cell-free DNA: technical advances and challenges. Curr. Opin. Genet. Dev. 42, 48–55 (2017).
Reckamp, K. L. et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J. Thorac. Oncol. 11, 1690–1700 (2016).
Google Scholar
Swanson, P. et al. Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1. 5, and LCx^A R○ HIV RNA quantitative assays. J. Virol. Methods 137, 184–192 (2006).
Google Scholar
Castle, P. E. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 12, 880–890 (2011).
Google Scholar
Sandri, M. T. et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin. Microbiol. 44, 2141–2146 (2006).
Google Scholar
Misawa, Y. et al. Application of loop-mediated isothermal amplification technique to rapid and direct detection of methicillin-resistant Staphylococcus aureus (MRSA) in blood cultures. J. Infect. Chemother. 13, 134–140 (2007).
Google Scholar
Ethridge, S. F. et al. Performance of the Aptima HIV-1 RNA qualitative assay with 16- and 32-member specimen pools. J. Clin. Microbiol. 48, 3343–3345 (2010).
Google Scholar
Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
Google Scholar
Mok, T. S. et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N. Engl. J. Med. 376, 629–640 (2017).
Google Scholar
Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604–8610 (2011).
Google Scholar
Newton, C. R. et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17, 2503–2516 (1989).
Google Scholar
Das, J. et al. An electrochemical clamp assay for direct, rapid analysis of circulating nucleic acids in serum. Nat. Chem. 7, 569–575 (2015).
Google Scholar
Lin, M. et al. Electrochemical detection of nucleic acids, proteins, small molecules and cells using a DNA-nanostructure-based universal biosensing platform. Nat. Protoc. 11, 1244–1263 (2016).
Google Scholar
Gootenberg, J. S. et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 356, 438–442 (2017).
Google Scholar
Dressman, D., Yan, H., Traverso, G., Kinzler, K. W. & Vogelstein, B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc. Natl Acad. Sci. USA 100, 8817–8822 (2003).
Google Scholar
Khoo, C. et al. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transl. Lung Cancer Res. 4, 126–141 (2015).
Google Scholar
Ragoussis, J. Genotyping technologies for genetic research. Annu. Rev. Genomics Hum. Genet. 10, 117–133 (2009).
Google Scholar
Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108–112 (2013).
Google Scholar
Wetterstrand, K. A. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP) (National Human Genome Research Institute, accessed 19 July 2018); www.genome.gov/sequencingcostsdata
Laver, T. et al. Assessing the performance of the Oxford Nanopore Technologies MinION. Biomol. Detect. Quantif. 3, 1–8 (2015).
Google Scholar
Carneiro, M. O. et al. Pacific biosciences sequencing technology for genotyping and variation discovery in human data. BMC Genomics 13, 375 (2012).
Google Scholar
Taylor, A. D., Micheel, C. M., Anderson, I. A., Levy, M. A. & Lovly, C. M. The path (way) less traveled: a pathway-oriented approach to providing information about precision cancer medicine on My Cancer Genome. Transl. Oncol. 9, 163–165 (2016).
Google Scholar
Diehn, M. et al. Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumour DNA (ctDNA). J. Clin. Oncol. 35, 3591 (2017).
Couraud, S. et al. Non-invasive diagnosis of actionable mutations by deep sequencing of circulating-free DNA in non-small-cell lung cancer: findings from BioCAST/IFCT-1002. Clin. Cancer Res. 20, 4613–4624 (2014).
Google Scholar
Song, P. et al. Selective multiplexed enrichment for the detection and quantitation of low-fraction DNA variants via low depth sequencing. Nat. Biomed. Eng. 5, 690–701 (2021).
Google Scholar
Meyer, M. & Kircher, M. Illumina sequencing library preparation for highly multiplexed target capture and sequencing. Cold Spring Harb. Protoc. 2010, pdb.prot5448 (2010).
Google Scholar
Hovelson, D. H. et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumours. Neoplasia 17, 385–399 (2015).
Google Scholar
Dupuis, J. R. et al. HiMAP: robust phylogenomics from highly multiplexed amplicon sequencing. Mol. Ecol. Resour. 18, 1000–1019 (2018).
Google Scholar
Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508–14513 (2012).
Google Scholar
Blakely, C. M. et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat. Genet. 49, 1693–1704 (2017).
Google Scholar
Kinde, I. et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl Acad. Sci. USA 108, 9530–9535 (2011).
Google Scholar
Lo, Y. D. et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci. Transl. Med. 2, 61ra91 (2010).
Google Scholar
Thierry, A. R. et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 38, 6159–6175 (2010).
Google Scholar
Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164, 57–68 (2016).
Google Scholar
Mouliere, F. et al. Enhanced detection of circulating tumour DNA by fragment size analysis. Sci. Transl. Med. 10, 466 (2018).
Thakur, B. K. et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24, 766–769 (2014).
Google Scholar
Balaj, L. et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011).
Google Scholar
Zhang, J. X. et al. Predicting DNA hybridization kinetics from sequence. Nat. Chem. 10, 91–98 (2018).
Google Scholar
Newman, A. M. et al. Integrated digital error suppression for improved detection of circulating tumour DNA. Nat. Biotechnol. 34, 547–555 (2016).
Google Scholar
Kou, R. et al. Benefits and challenges with applying unique molecular identifiers in next generation sequencing to detect low frequency mutations. PLoS ONE 11, e0146638 (2016).
Google Scholar
Jabara, C. B., Jones, C. D., Roach, J., Anderson, J. A. & Swanstrom, R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc. Natl Acad. Sci. USA 108, 20166–20171 (2011).
Google Scholar
Abascal, F. et al. Somatic mutation landscapes at single-molecule resolution. Nature 593, 405–410 (2021).
Google Scholar
Cohen, J. D. et al. Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. Nat. Biotechnol. 39, 1220–1227 (2021).
Google Scholar
Pel, J. et al. Nonlinear electrophoretic response yields a unique parameter for separation of biomolecules. Proc. Natl Acad. Sci. USA 106, 14796–14801 (2009).
Google Scholar
Kidess, E. et al. Mutation profiling of tumour DNA from plasma and tumour tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget 6, 2549–2561 (2015).
Google Scholar
Song, C. & Liu et al. Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment. Nucleic Acids Res. 44, e146 (2016).
Google Scholar
Seyama, T. et al. A novel blocker-PCR method for detection of rare mutant alleles in the presence of an excess amount of normal DNA. Nucleic Acids Res. 20, 2493–2496 (1992).
Google Scholar
Arcila, M., Lau, C., Nafa, K. & Ladanyi, M. Detection of KRAS and BRAF mutations in colorectal carcinoma: roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J. Mol. Diagnostics 13, 64–73 (2011).
Google Scholar
Orum, H. et al. Single base pair mutation analysis by PNA directed PCR clamping. Nucleic Acids Res. 21, 5332–5336 (1993).
Google Scholar
Milbury, C. A., Li, J. & Makrigiorgos, G. M. Ice-COLD-PCR enables rapid amplification and robust enrichment for low-abundance unknown DNA mutations. Nucleic Acids Res. 39, e2 (2011).
Google Scholar
Li, J. et al. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat. Med. 14, 579–584 (2008).
Google Scholar
Zuo, Z. et al. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod. Pathol. 22, 1023–1031 (2009).
Google Scholar
Wu, L. R. et al. Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification. Nat. Biomed. Eng. 1, 714–723 (2017).
Google Scholar
Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127–1133 (2013).
Google Scholar
Mertens, F., Johansson, B., Fioretos, T. & Mitelman, F. The emerging complexity of gene fusions in cancer. Nat. Rev. Cancer 15, 371–381 (2015).
Google Scholar
Wang, Q. et al. Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives. Brief. Bioinform. 14, 506–519 (2012).
Google Scholar
Maher, C. A. et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 458, 97–101 (2009).
Google Scholar
Zhao, Q. et al. Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc. Natl Acad. Sci. USA 106, 1886–1891 (2009).
Google Scholar
Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134–1140 (2013).
Google Scholar
Whale, A. S. et al. Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res. 40, e82 (2012).
Google Scholar
Pinkel, D. et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet. 20, 207–211 (1998).
Google Scholar
Chiu, R. W. et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. Brit. Med. J. 342, c7401 (2011).
Google Scholar
Kops, G. J., Weaver, B. A. & Cleveland, D. W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 5, 773–785 (2004).
Mandel, P. & Metais, P. Les acides nucleiques du plasma sanguin chez la homme. C. R. Seances Soc. Biol. Fil. 142, 241–243 (1948).
Google Scholar
Bettegowda, C. et al. Detection of circulating tumour DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224 (2014).
Aravanis, A. M., Lee, M. & Klausner, R. D. Next-generation sequencing of circulating tumour DNA for early cancer detection. Cell 168, 571–574 (2017).
Google Scholar
Razavi, P. et al. Cell-free DNA (cfDNA) mutations from clonal hematopoiesis: implications for interpretation of liquid biopsy tests. J. Clin. Oncol. 35, 11526 (2017).
Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).
Google Scholar
Schwarzenbach, H., Nishida, N., Calin, G. A. & Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 11, 145–156 (2014).
Google Scholar
Azmi, A. S., Bao, B. & Sarkar, F. H. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 32, 623–642 (2013).
Google Scholar
De Mattos-Arruda, L. et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat. Rev. Clin. Oncol. 10, 377–389 (2013).
Google Scholar
de Bono, J. S. et al. Circulating tumour cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302–6309 (2008).
Google Scholar
Potapov, V. & Ong, J. L. Examining sources of error in PCR by single-molecule sequencing. PLoS ONE 12, e0181128 (2017).
Google Scholar
Schirmer, M. et al. Insight into biases and sequencing errors for amplicon sequencing with the Illumina MiSeq platform. Nucleic Acids Res. 43, e37 (2015).
Google Scholar
Schirmer, M., Damore, R., Ijaz, U. Z., Hall, N. & Quince, C. Illumina error profiles: resolving fine-scale variation in metagenomic sequencing data. BMC Bioinformatics 17, 125 (2016).
Google Scholar
Minoche, A. E., Dohm, J. C. & Himmelbauer, H. Evaluation of genomic high-throughput sequencing data generated on Illumina HiSeq and genome analyzer systems. Genome Biol. 12, R112 (2011).
Google Scholar
Jain, M. et al. Nanopore sequencing and assembly of a human genome with ultra-long reads. Nat. Biotechnol. 36, 338–345 (2018).
Google Scholar
Quail, M. A. et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 13, 341 (2012).
Google Scholar
Leary, R. J. et al. Development of personalized tumour biomarkers using massively parallel sequencing. Sci. Transl. Med. 2, 20ra14 (2010).
Google Scholar
